Last reviewed · How we verify
Ibuprofen 4%
At a glance
| Generic name | Ibuprofen 4% |
|---|---|
| Sponsor | Berlin-Chemie AG Menarini Group |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Paracervical Block With Combined Ketorolac and Lidocaine for Osmotic Dilator Placement (PHASE2)
- Comparing Over the Counter Pain Medicines for Discomfort in Crohn's Disease (AVID-CD) (NA)
- ERAS (Enhanced Recovery After Surgery) and Multimodal Analgesia in Laparoscopic Cholecystectomy
- A Bioequivalence Study of Advil Tablet (Mini) (Ibuprofen 200 mg) Versus Advil Tablet (Ibuprofen 200 mg) in Healthy Adult Subjects Under Fasted Conditions and Bioavailability Assessment of Advil Tablet (Mini) Under Fed Conditions (PHASE1)
- Criteria for Advanced Prosthetic Foot Prescription (NA)
- Comparing Analgesic Regimen Effectiveness and Safety for Surgery for Kids Trial (PHASE4)
- Preemptive IV Ibuprofen for Neurocognitive Recovery and Analgesic Needs After Inguinal Hernia Surgery (PHASE4)
- Total Knee Arthroplasty (TKA) Study of HTX-011 in an Multimodal Analgesic Regimen (MMA) Regimen (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ibuprofen 4% CI brief — competitive landscape report
- Ibuprofen 4% updates RSS · CI watch RSS
- Berlin-Chemie AG Menarini Group portfolio CI